Molecular immunology department

Molecular immunology department owns everal technology platforms including ELISA/ELISpot, reverse dot blot, and time- resolved fluorescence. The product lines developed can be used for TB infection screening, diagnosis and detection of drug resistance. Among them is the tuberculosis T cell immune detection kit with independent intellectual property (patented in China), which has won CFDA clinical approval and production license; the in- development kit for rapid diagnosis of tuberculosis drug sensitivity based on reverse dot blot will help to achieve an all- round and rapid detection of MDR- TB; the in- development tuberculosis molecular diagnostic kit is simple to use and does not require any special equipment, suitable for the needs of tuberculosis prevention and control at all levels of disease control facilities.
    Molecular immunology department has taken part in the major projects of the 12th five- year plan and has established a long- term cooperation with Institute of Microbiology of Chinese Academy of Sciences, Peking University, Tsinghua University, Chinese Center for Disease Control and Prevention and Beijing Chest Hospital. The platform established for the conversion of biological reagents ensures sustained innovation of the product lines.

分子诊断部

分子诊断部以microRNA为切入点，专注于重大癌症、艾滋病、结核病、肝病等microRNA诊断试剂盒的研制，并提供从microRNA表达谱检测到功能研究的全套技术服务。本平台采用自主知识产权发明专利"三步法qPCR"技术和独特的外源RNA对照设计，实现血清、血浆、组织、细胞、石蜡组织切片中microRNA表达量的检测。

艾滋病快速进展microRNA标志物已申报获得5项国家发明专利，乳腺癌特异性microRNA标志物已申报获得4项国家发明专利，乙肝、肝硬化特异性microRNA标志物已申报3项国家发明专利，肝硬化miRNA诊断试剂盒已启动注册申报程序。